OBI Pharma : The Company’s BOD resolved to forfeit the subscription of AP Biosciences’ cash capital increase and distribute the rights to its shareholders
The Company's BOD resolved to forfeit the
subscription of AP Biosciences' cash capital increase
and distribute the rights to its shareholders
Date of events
2022/08/08
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/08/08
2.Company name:OBI Pharma Inc.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:Not applicable
5.Cause of occurrence:
In accordance with related laws and regulations, to coordinate with AP
Biosciences' future plan of shareholding dispersal after IPO, to protect
shareholders' interests of the Company, and to share the business results
of AP Biosciences, the Company's Board of Directors decide to forfeit all
the preemptive rights of AP Biosciences' cash capital increase and
distribute the rights to shareholders of OBI.
6.Countermeasures:None
7.Any other matters that need to be specified:
(1)AP Biosciences' Board of Directors resolved to issue common shares
through cash capital increase. The total amount of cash issuance is
16,000,000 shares, with a par value of NT$10 per share and a issue
price of NT$50. The total fund raised is expected to be NT$800,000,000.
Pursuant to Article 267 of the Company Act, 10% of the total new
shares, 1,600,000 shares, are reserved for employees who are eligible.
Other 90% of the total new shares, 14,400,000 shares, will be
subscribed by original shareholders based on the shareholding ratio
stated on the register of shareholders on the reference date.
(2)In accordance with related laws and regulations, to coordinate with AP
Biosciences' future plan of shareholding dispersal after IPO, to
protect shareholders' interests of the Company, and to share the
business results of AP Biosciences, the Company's Board of Directors
decide to forfeit all the preemptive rights of AP Biosciences' cash
capital increase and distribute the rights to shareholders of OBI.
Based on the shareholding ratio stated on the register of shareholders
on the book closure date, each thousand shares of OBI bears the
subscription rights for 34.3016 shares of AP Biosciences. The Chairman
of AP Biosciences is authorized to contact specific persons for
purchase at the issue price for shares unsubscripted by shareholders or
fractional shares.
(3)The Company's shareholding ratios of AP Biosciences will decrease from
54.62% to 41.12% after the forfeiture of preemptive rights of AP
Biosciences' cash capital increase.
(4)The Chairman of the Company is authorized to decide any other matters
not covered herein related to the forfeiture of subscription of AP
Biosciences' cash capital increase, which will be sent to 2023 Annual
Shareholders' Meeting for ratification.
Attachments
Original Link
Original Document
Permalink
Disclaimer
OBI Pharma Inc. published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 August 2022 08:43:08 UTC.
OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.
OBI Pharma : The Company’s BOD resolved to forfeit the subscription of AP Biosciences’ cash capital increase and distribute the rights to its shareholders
OBI PHARMA, INC. 
